Skip to main content

LAB

Stock
Health Care
Diagnostics & Research

Performance overview

LAB Price
Price Chart

Forward-looking statistics

Beta
2.10
Risk
85.83%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.

Company info

SectorHealth Care
IndustryDiagnostics & Research
Employees498
Market cap$858.2M

Fundamentals

Enterprise value$175.2M
Revenue$169.7M
Revenue per employee—
Profit margin-78.24%
Debt to equity118.03

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$0.32
Dividend per share—
Revenue per share$0.45
Avg trading volume (30 day)$3M
Avg trading volume (10 day)$6M
Put-call ratio—

Macro factor sensitivity

Growth+0.4
Credit+4.8
Liquidity-1.8
Inflation-4.5
Commodities+0.9
Interest Rates-1.1

Valuation

Dividend yield0.00%
PEG Ratio-6.14
Price to sales2.87
P/E Ratio-6.14
Enterprise Value to Revenue1.03
Price to book1.09

Upcoming events

Next earnings dayMay 7, 2025
Next dividend day—
Ex. dividend day—

News

Astera Labs Drops 33% Year to Date: Buy, Sell or Hold the Stock?

ALAB's strong portfolio makes its top-line growth prospects bright. However, stiff competition and stretched valuation make the stock a risky bet.

Zacks Investment Research (July 14, 2025)
Buy, Sell Or Hold Astera Labs Stock?

Astera Labs (NASDAQ:ALAB), a firm specializing in semiconductor-based connectivity solutions for cloud and AI infrastructure, experienced a stock increase of nearly 8% on Wednesday. Although there wasn't significant stock-specific news to justify such a substantial change, there are several compelling reasons for investors to show growing interest in the stock.

Forbes (July 11, 2025)
Leading AI Stock Clears Key Hurdle Ahead of Earnings: Time to Buy?

This designer and manufacturer of semiconductor-based connectivity solutions is breaking out.

Zacks Investment Research (July 10, 2025)
Standard BioTools (LAB) Reports Q1 Loss, Tops Revenue Estimates

Standard BioTools (LAB) came out with a quarterly loss of $0.04 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.23 per share a year ago.

Zacks Investment Research (May 6, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free